Previous 10 |
home / stock / swtuy / swtuy news
STOCKHOLM , Jan. 24, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) announced today that it has completed the acquisition from AstraZeneca of rights to Synagis® (palivizumab) in the US as well as rights to participate in 50 per cent of the future...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Bio S/Adr Company Name:
SWTUY Stock Symbol:
OTCMKTS Market:
In March, Sanofi (NASDAQ: SNY) and its Sweden-based partner Sobi (OTC: SWTUY) announced positive phase 3 clinical trial results for efanesoctocog alfa, their jointly developed drug candidate for severe hemophilia A. The two companies expect to begin submitting applicatio...
Shares of drugmaker Dova Pharmaceuticals (NASDAQ: DOVA) rose by 86.5% in September, according to data provided by S&P Global Market Intelligence . This added to Dova's big gains in 2019, piggybacking on a June jump of 59.9%. Year to date, the company's shares have skyrocketed 271.2%. A...
Shares of Dova Pharmaceuticals (NASDAQ: DOVA) , a biopharmaceutical company focused on rare blood-based diseases, leapt higher following a generous buyout offer. The European rare-disease drugmaker Sobi (OTC: SWTUY) will acquire Dova for up to $29 per share, which is around 45% ...